In a recent retrospective, observational, multinational study in patients with psoriasis and latent TB infection, IL-17 or IL-23 inhibitors did not appear to have an increased risk of TB reactivation and were recommended to be preferred over TNFis especially when TB reactivation is a concern [35]. The gene discussed is IL17A; the disease is tuberculosis.